[go: up one dir, main page]

WO2008140782A3 - Compounds for enzyme inhibition - Google Patents

Compounds for enzyme inhibition Download PDF

Info

Publication number
WO2008140782A3
WO2008140782A3 PCT/US2008/005997 US2008005997W WO2008140782A3 WO 2008140782 A3 WO2008140782 A3 WO 2008140782A3 US 2008005997 W US2008005997 W US 2008005997W WO 2008140782 A3 WO2008140782 A3 WO 2008140782A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
based compounds
compounds
enzyme inhibition
proteasome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/005997
Other languages
French (fr)
Other versions
WO2008140782A2 (en
Inventor
Han-Jie Zhou
Guy J Laidig
Kevin D Shenk
Congcong M Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onyx Pharmaceuticals Inc
Original Assignee
Proteolix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteolix Inc filed Critical Proteolix Inc
Publication of WO2008140782A2 publication Critical patent/WO2008140782A2/en
Publication of WO2008140782A3 publication Critical patent/WO2008140782A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profile.
PCT/US2008/005997 2007-05-10 2008-05-09 Compounds for enzyme inhibition Ceased WO2008140782A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92875807P 2007-05-10 2007-05-10
US60/928,758 2007-05-10

Publications (2)

Publication Number Publication Date
WO2008140782A2 WO2008140782A2 (en) 2008-11-20
WO2008140782A3 true WO2008140782A3 (en) 2008-12-31

Family

ID=39743821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/005997 Ceased WO2008140782A2 (en) 2007-05-10 2008-05-09 Compounds for enzyme inhibition

Country Status (1)

Country Link
WO (1) WO2008140782A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174076A (en) 2004-04-15 2011-09-07 普罗特奥里克斯公司 Compounds for proteasome enzyme inhibition
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
SG185963A1 (en) 2004-05-10 2012-12-28 Onyx Therapeutics Inc Compounds for enzyme inhibition
LT2623113T (en) 2005-11-09 2017-07-10 Onyx Therapeutics, Inc. Compound for enzyme inhibition
PL2041158T3 (en) 2006-06-19 2013-08-30 Onyx Therapeutics Inc Peptide epoxyketones for proteasome inhibition
ES2684340T3 (en) 2007-10-04 2018-10-02 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and amino acid ketoepoxide synthesis
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
EP2349313A4 (en) 2008-10-21 2012-08-29 Onyx Therapeutics Inc Combination therapy with peptide epoxyketones
UA107569C2 (en) * 2009-03-20 2015-01-26 Crystalline Tripeptide Inhibitors of Epoxyketone Protease
AU2013203857B2 (en) * 2009-03-20 2016-05-19 Onyx Therapeutics, Inc. Crystalline tripeptide epoxy ketone protease inhibitors
TWI504598B (en) * 2009-03-20 2015-10-21 Onyx Therapeutics Inc Crystalline tripeptide ketone ketone protease inhibitor
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
EA201290844A1 (en) 2010-03-01 2013-03-29 Оникс Терапьютикс, Инк. COMPOUNDS FOR INHIBITION BY IMMUNOPROTEAS
PL2814849T3 (en) 2012-02-15 2020-07-27 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
CN103570806B (en) * 2012-07-26 2020-04-07 圣特莱国际公司 Polypeptide epoxy ketone compound
HK1213585A1 (en) 2012-10-22 2016-07-08 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
TW201422255A (en) 2012-10-24 2014-06-16 Onyx Therapeutics Inc Modified release formulations for oprozomib
KR102360356B1 (en) 2014-07-14 2022-02-08 센트랙스 인터내셔널, 아이엔씨. Epoxyketone compounds for enzyme inhibition
FI3183295T3 (en) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
CN105949279A (en) * 2016-04-27 2016-09-21 浙江大学 Method for preparing proteasome inhibitor Oprozomib and analogs thereof
CN110092813B (en) * 2019-06-05 2021-05-11 南京师范大学 A kind of tripeptide propylene oxide derivative and its preparation method and use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111008A2 (en) * 2004-05-10 2005-11-24 Proteolix, Inc. Compounds for enzyme inhibition
WO2006045066A2 (en) * 2004-10-20 2006-04-27 Proteolix, Inc. Labeled compounds for proteasome inhibition
WO2007056464A1 (en) * 2005-11-09 2007-05-18 Proteolix, Inc. Compounds for enzyme inhibition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111008A2 (en) * 2004-05-10 2005-11-24 Proteolix, Inc. Compounds for enzyme inhibition
WO2006045066A2 (en) * 2004-10-20 2006-04-27 Proteolix, Inc. Labeled compounds for proteasome inhibition
WO2007056464A1 (en) * 2005-11-09 2007-05-18 Proteolix, Inc. Compounds for enzyme inhibition

Also Published As

Publication number Publication date
WO2008140782A2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2008140782A3 (en) Compounds for enzyme inhibition
MY145757A (en) Compounds for enzyme inhibition
WO2005111008A3 (en) Compounds for enzyme inhibition
WO2005105827A3 (en) Compounds for proteasome enzyme inhibition
LTPA2016010I1 (en) Compounds for the inhibition of proteasome enzymes
CL2012000738A1 (en) Indole-derived heterocyclic compounds, xanthine oxidase inhibitors; pharmaceutical composition comprising them; preparation procedure; and use in the treatment of diseases such as hyperuricemia, gout, heart failure, hypertension, diabetes, hyperlipidemia, obesity, atherosclerosis, among others.
CL2012002356A1 (en) Heterocyclic acid compounds derived from bisyl-linked aryltriazolones, vasopressin receptor inhibitors v1a and v2; preparation procedure; pharmaceutical composition; and its use to treat and / or prevent acute and chronic heart failure, hyponatremia, among others.
MX342898B (en) Therapeutic regimens.
EA201290229A1 (en) SPIROLACTAM DERIVATIVES AND THEIR APPLICATION
WO2012030949A3 (en) B2-glycoprotein i peptide inhibitors
WO2008130591A3 (en) Using trefoil polypeptides to treat eye lesions associated with ophthalmic procedures
CR9962A (en) ENZYMATIC INHIBITION COMPOUNDS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08767663

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08767663

Country of ref document: EP

Kind code of ref document: A2